JP2017521374A5 - - Google Patents

Download PDF

Info

Publication number
JP2017521374A5
JP2017521374A5 JP2016569875A JP2016569875A JP2017521374A5 JP 2017521374 A5 JP2017521374 A5 JP 2017521374A5 JP 2016569875 A JP2016569875 A JP 2016569875A JP 2016569875 A JP2016569875 A JP 2016569875A JP 2017521374 A5 JP2017521374 A5 JP 2017521374A5
Authority
JP
Japan
Prior art keywords
inhibitor
kidney
inhibitors
use according
donor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2016569875A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017521374A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/032499 external-priority patent/WO2015183842A1/en
Publication of JP2017521374A publication Critical patent/JP2017521374A/ja
Publication of JP2017521374A5 publication Critical patent/JP2017521374A5/ja
Withdrawn legal-status Critical Current

Links

JP2016569875A 2014-05-29 2015-05-27 臓器の虚血再灌流傷害を予防するための方法及び組成物 Withdrawn JP2017521374A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462004239P 2014-05-29 2014-05-29
US62/004,239 2014-05-29
PCT/US2015/032499 WO2015183842A1 (en) 2014-05-29 2015-05-27 Methods and compositions for preventing ischemia reperfusion injury in organs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020074549A Division JP2020128383A (ja) 2014-05-29 2020-04-20 臓器の虚血再灌流傷害を予防するための方法及び組成物

Publications (2)

Publication Number Publication Date
JP2017521374A JP2017521374A (ja) 2017-08-03
JP2017521374A5 true JP2017521374A5 (enExample) 2018-06-28

Family

ID=53398201

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016569875A Withdrawn JP2017521374A (ja) 2014-05-29 2015-05-27 臓器の虚血再灌流傷害を予防するための方法及び組成物
JP2020074549A Pending JP2020128383A (ja) 2014-05-29 2020-04-20 臓器の虚血再灌流傷害を予防するための方法及び組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020074549A Pending JP2020128383A (ja) 2014-05-29 2020-04-20 臓器の虚血再灌流傷害を予防するための方法及び組成物

Country Status (18)

Country Link
US (3) US20170081665A1 (enExample)
EP (2) EP3149172B1 (enExample)
JP (2) JP2017521374A (enExample)
KR (1) KR20170007492A (enExample)
CN (2) CN106661579B (enExample)
AU (1) AU2015267160B2 (enExample)
BR (1) BR112016028009A2 (enExample)
CA (1) CA2949109A1 (enExample)
DK (2) DK3444349T3 (enExample)
ES (2) ES2683869T3 (enExample)
HU (2) HUE040092T2 (enExample)
IL (2) IL248912A0 (enExample)
LT (2) LT3444349T (enExample)
MX (2) MX373950B (enExample)
PL (2) PL3444349T3 (enExample)
PT (2) PT3149172T (enExample)
SI (2) SI3444349T1 (enExample)
WO (1) WO2015183842A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3043768A1 (en) 2016-11-29 2018-06-07 PureTech Health LLC Exosomes for delivery of therapeutic agents
WO2019140176A1 (en) * 2018-01-12 2019-07-18 University Of Massachusetts Methods for preventing graft ischemia reperfusion injury during ex vivo machine perfusion preservation
GB202016863D0 (en) * 2020-10-23 2020-12-09 Causeway Therapeutics Ltd Microrna-29 compounds, compositions and uses in therapy
JP2024539149A (ja) * 2021-12-22 2024-10-28 エヌエー ヴァクシン インスティテュート 虚血・再灌流障害を予防または治療するための組成物及びその用途
KR20240154159A (ko) * 2023-04-17 2024-10-25 재단법인 아산사회복지재단 miR-223을 유효성분으로 포함하는 간 손상 예방 또는 치료용 조성물
CN118460648B (zh) * 2024-07-10 2025-01-28 凯莱英医药集团（天津）股份有限公司 一种qpi-1002的制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5861254A (en) 1997-01-31 1999-01-19 Nexstar Pharmaceuticals, Inc. Flow cell SELEX
JPH06508022A (ja) 1991-02-21 1994-09-14 ギリアド　サイエンシズ，インコーポレイテッド 生体分子に特異的なアプタマーおよび生産方法
US5756291A (en) 1992-08-21 1998-05-26 Gilead Sciences, Inc. Aptamers specific for biomolecules and methods of making
ES2162863T3 (es) 1993-04-29 2002-01-16 Unilever Nv Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae.
IL144294A0 (en) 1999-01-29 2002-05-23 Univ Illinois P53 inhibitors and therapeutic use of the same
US6376190B1 (en) 2000-09-22 2002-04-23 Somalogic, Inc. Modified SELEX processes without purified protein
EP1737879B1 (en) 2004-04-19 2012-10-10 Archemix LLC Aptamer-mediated intracellular delivery of therapeutic oligonucleotides
AU2005288522B2 (en) 2004-09-28 2012-06-28 Quark Pharmaceuticals, Inc. Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases
EP1989307B1 (en) 2006-02-08 2012-08-08 Quark Pharmaceuticals, Inc. NOVEL TANDEM siRNAS
US7910566B2 (en) * 2006-03-09 2011-03-22 Quark Pharmaceuticals Inc. Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA
WO2009001359A2 (en) 2007-06-27 2008-12-31 Quark Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of pro-apoptotic genes
RU2487716C2 (ru) * 2007-10-03 2013-07-20 Кварк Фармасьютикалс, Инк. Новые структуры малых интерферирующих рнк (sirna)
WO2009155504A2 (en) * 2008-06-20 2009-12-23 The Children's Medical Center Corporation Methods for the modulation of angiogenesis
CN102458418B (zh) * 2009-06-08 2015-09-16 夸克制药公司 一种寡核苷酸化合物的制药用途
AU2010324658A1 (en) 2009-11-26 2012-05-03 Quark Pharmaceuticals, Inc. siRNA compounds comprising terminal substitutions
WO2011084193A1 (en) 2010-01-07 2011-07-14 Quark Pharmaceuticals, Inc. Oligonucleotide compounds comprising non-nucleotide overhangs
JPWO2011138966A1 (ja) 2010-05-06 2013-07-22 ダイヤニトリックス株式会社 微生物触媒を用いたアクリルアミドの製造方法
WO2012068381A2 (en) * 2010-11-17 2012-05-24 The University Of North Carolina At Chapel Hill Protection of renal tissues from schema through inhibition of the proliferative kisses cdk4 and cdk6
AU2011338682B2 (en) 2010-12-06 2017-04-27 Quark Pharmaceuticals, Inc. Double stranded oligonucleotide compounds comprising threose modifications
US9176487B2 (en) * 2011-10-24 2015-11-03 Mayo Foundation For Medical Education And Research Methods and materials for reducing the risk of infections
ES2704855T3 (es) * 2012-09-12 2019-03-20 Quark Pharmaceuticals Inc Moléculas de oligonucleótido de doble cadena para p53 y métodos de uso de las mismas

Similar Documents

Publication Publication Date Title
JP2017521374A5 (enExample)
JP2022501040A5 (enExample)
JP2022031772A5 (enExample)
JP2020511521A5 (enExample)
JP2019504112A5 (enExample)
US9868953B2 (en) Methods and compositions for preventing ischemia reperfusion injury in organs
JP2019513384A5 (enExample)
US20190071670A1 (en) Methods Of Treatment For Alpha-1 Antitrypsin Deficiency
Kanold et al. Extracorporeal photochemotherapy for graft versus host disease in pediatric patients
JP2021515042A (ja) ムチンに作用するプロテアーゼを含む製剤
Li et al. Modular assembled biomimetic nanobubbles for synergistic therapy of ischemic stroke via cascade modulation thrombo-inflammatory network
JP6928611B2 (ja) 組合せ
US20220257614A1 (en) Use of 12-lipoxygenase inhibitors in the treatment of covid-19
JP7428352B2 (ja) ビタミンｅならびにがん治療用組成物および方法
JP2023541214A (ja) オルガノイドおよび抗炎症剤を含む炎症性腸疾患の予防または治療用薬学組成物
CN118202046A (zh) 具有降低的脱靶效应的经修饰的小干扰rna分子
CN113262226B (zh) 利舒地尔在制备细菌感染治疗药物中的应用
CN108348539A (zh) 用于治疗肿瘤的方法
Chen et al. SAT-370 miR-466o-3p promotes podocyte injury through targeting WT1
WO2023034568A1 (en) Specific therapeutic medical marijuana doses for stress and pain
EP4619020A1 (en) Composition and method for prolong survival of transplant and recipient
WO2024173624A1 (en) Compositions and methods for the treatment of sepsis
CN120361239A (zh) 一种用于治疗甲基苯丙胺成瘾的纳米载药递送系统及其制备方法和药物制剂
KR100829450B1 (ko) ＭＤＲ１에 대한 ｓｈＲＮＡ 및 티미딘 인산화효소를발현하는 재조합 벡터 및 이의 용도
JP4638563B2 (ja) 臓器移植障害予防治療剤